These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 14679970)

  • 1. Injectable drug dampens bone loss.
    Health News; 2003 Dec; 9(12):11. PubMed ID: 14679970
    [No Abstract]   [Full Text] [Related]  

  • 2. [Halved fracture risk through 10% bone increase--an illusion in the therapy of osteoporosis?].
    Kruse HP
    Dtsch Med Wochenschr; 1998 Apr; 123(15):472-7. PubMed ID: 9581164
    [No Abstract]   [Full Text] [Related]  

  • 3. [Biphosphonates for the prevention of osteoporosis in postmenopausal women with a low bone mass].
    Pelayo M; Agra Y
    Med Clin (Barc); 2004 Mar; 122(8):304-10. PubMed ID: 15030743
    [No Abstract]   [Full Text] [Related]  

  • 4. [Monthly tablet in postmenopausal osteoporosis].
    Krankenpfl J; 2005; 43(7-10):216. PubMed ID: 16515288
    [No Abstract]   [Full Text] [Related]  

  • 5. A once-yearly IV bisphosphonate for osteoporosis.
    Med Lett Drugs Ther; 2007 Nov; 49(1273):89-90. PubMed ID: 17975523
    [No Abstract]   [Full Text] [Related]  

  • 6. Use of bisphosphonates in the management of postmenopausal osteoporosis.
    Papapoulos SE
    Ann N Y Acad Sci; 2011 Feb; 1218():15-32. PubMed ID: 20946579
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bisphosphonate dose and incidence of fractures in postmenopausal osteoporosis.
    Makras P; Hamdy NA; Zwinderman AH; Ballieux BE; Papapoulos SE
    Bone; 2009 May; 44(5):766-71. PubMed ID: 19442613
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bisphosphonate addition to stable hormone replacement therapy increases bone mineral density in postmenopausal women.
    Boulos P; Sebaldt RJ; Goldsmith CH
    J Rheumatol; 2002 May; 29(5):1110-1. PubMed ID: 12022339
    [No Abstract]   [Full Text] [Related]  

  • 9. Is it feasible to adjust bisphosphonate dose according to bone mineral density value in postmenopausal breast cancer patients with bone metastases?
    Delibasi T; Akkus NI; Altundag O; Pinar T; Altundag K
    Med Hypotheses; 2006; 66(6):1254-5. PubMed ID: 16413688
    [No Abstract]   [Full Text] [Related]  

  • 10. Optimizing the management of postmenopausal osteoporosis with bisphosphonates: the emerging role of intermittent therapy.
    Miller PD
    Clin Ther; 2005 Apr; 27(4):361-76. PubMed ID: 15922811
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevent, treat and maintain: a new goal for osteoporosis management in clinical practice.
    Gandolini G; Migliaccio S; Bevilacqua M; Lello S; Malavolta N
    Aging Clin Exp Res; 2004 Jun; 16 Suppl(3):37-41. PubMed ID: 15506700
    [No Abstract]   [Full Text] [Related]  

  • 12. [Expert group consensus: prevention, diagnosis and treatment of bone loss and osteoporosis in postmenopausal breast cancer patients after aromatase inhibitor therapy].
    Xiu Bing-He ;
    Zhonghua Zhong Liu Za Zhi; 2013 Nov; 35(11):876-9. PubMed ID: 24447490
    [No Abstract]   [Full Text] [Related]  

  • 13. Postmenopausal osteoporosis: therapeutic options.
    Genazzani AR; Gambacciani M; Schneider HP; Christiansen C;
    Climacteric; 2005 Jun; 8(2):99-109. PubMed ID: 16096166
    [No Abstract]   [Full Text] [Related]  

  • 14. Intravenous zoledronic acid in postmenopausal women with low bone mineral density.
    Reid IR; Brown JP; Burckhardt P; Horowitz Z; Richardson P; Trechsel U; Widmer A; Devogelaer JP; Kaufman JM; Jaeger P; Body JJ; Brandi ML; Broell J; Di Micco R; Genazzani AR; Felsenberg D; Happ J; Hooper MJ; Ittner J; Leb G; Mallmin H; Murray T; Ortolani S; Rubinacci A; Saaf M; Samsioe G; Verbruggen L; Meunier PJ
    N Engl J Med; 2002 Feb; 346(9):653-61. PubMed ID: 11870242
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The cost effectiveness of zoledronic acid 5 mg for the management of postmenopausal osteoporosis in women with prior fractures: evidence from Finland, Norway and the Netherlands.
    Akehurst R; Brereton N; Ariely R; Lusa T; Groot M; Foss P; Boonen S
    J Med Econ; 2011; 14(1):53-64. PubMed ID: 21222506
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alendronate in postmenopausal osteoporosis.
    McGrath H
    N Engl J Med; 1996 Mar; 334(11):734; author reply 734-5. PubMed ID: 8594443
    [No Abstract]   [Full Text] [Related]  

  • 17. Bisphosphonates: when and for whom?
    Reid DM
    J Br Menopause Soc; 2003 Dec; 9(4):145, 155. PubMed ID: 15107255
    [No Abstract]   [Full Text] [Related]  

  • 18. Do not use bisphosphonate therapy indefinitely for fracture prevention.
    Prescrire Int; 2008 Oct; 17(97):214. PubMed ID: 19536944
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Osteoporosis--current concepts.
    Das SK; Misra R; Ramakrishnan S; Maheshwari A
    J Assoc Physicians India; 2001 Oct; 49():1007-11. PubMed ID: 11848307
    [No Abstract]   [Full Text] [Related]  

  • 20. Intravenous ibandronate (Boniva).
    Med Lett Drugs Ther; 2006 Aug 14-28; 48(1241-1242):68-9. PubMed ID: 16977282
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.